Traced to hERG rather than to serotonin, the QT prolongation in this MN660 Unit 8 brief is explained through delayed ventricular repolarization in a composite older woman on citalopram. Searches like "mn 660 unit 8 assignment example", "mn660 unit 8 sample" and "mn660 unit 8 example" land here.
A Silent Change on the ECG: Why Citalopram Lengthens the QT Interval
[Student Name]
Purdue University Global
MN660: PMHNP Neuroscience and Psychopharmacology
Unit 8 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. The regimen is bracketed; the brief explains a mechanism and leaves any decision about her medication to her prescriber.
The Finding
A composite 67-year-old woman has taken [citalopram, established dose] for depression for two years. A routine ECG before a minor procedure shows a QTc of [a longer value] compared with [a shorter value] a year ago. She reports no palpitations, fainting or dizziness. A silent effect is exactly where a mechanism explanation earns its place, because nothing she feels would reveal it.
Intended Target and Off-Target Channel
Citalopram's intended target is the serotonin transporter, which it blocks to raise synaptic serotonin. That action does not affect the heart's electrical cycle. The QT change comes from an off-target action: citalopram also blocks the hERG channel, which carries the rapid delayed rectifier potassium current, IKr, in heart muscle cells (Roden, 2004).
The Electrophysiology, Step by Step
IKr carries potassium out of heart cells during phase 3, the repolarization phase of the action potential.
Blocking IKr slows repolarization.
Slower repolarization lengthens the action potential.
A longer action potential appears on the surface ECG as a longer QT interval.
Why It Matters
Prolonged repolarization allows early afterdepolarizations, small electrical upswings before repolarization is complete. These can trigger torsades de pointes, a polymorphic ventricular tachycardia that can cause fainting or sudden death (Roden, 2004). Most people with a modestly longer QT never develop an arrhythmia; the prolongation is a marker of increased risk, not a diagnosis.
Factors That Deepen the Effect, Grouped by Mechanism
Weaker potassium current: low potassium and low magnesium, which reduce the same outward current and make IKr block more consequential. Slower heart rate: bradycardia stretches repolarization further and favors afterdepolarizations. Additive drugs: other medicines that block hERG, such as some antibiotics, antiemetics and antipsychotics. Patient factors: female sex and older age, both associated with longer baseline QT and greater susceptibility. She has two of these: female sex and age 67.
The Regulatory Record
In August 2011 the FDA issued a Drug Safety Communication on abnormal heart rhythms with high doses of citalopram, based on a thorough QT study showing dose-dependent QT prolongation, and it revised the communication in March 2012 (Food and Drug Administration, 2012). The communication set dose limits, with a lower limit for patients over 60; the figures are not reproduced here. In a large study of electronic health records, citalopram was associated with dose-dependent QTc prolongation, and escitalopram with a smaller effect (Castro et al., 2013).
The Limit of This Brief
This brief explains why the risk exists and how it arises. Whether her ECG finding calls for any change is a decision for her prescriber, who will weigh her depression, her other medicines and her electrolytes.
References
Castro, V. M., Clements, C. C., Murphy, S. N., Gainer, V. S., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., Smoller, J. W., & Perlis, R. H. (2013). QT interval and antidepressant use: A cross sectional study of electronic health records. BMJ, 346, f288. https://doi.org/10.1136/bmj.f288
Food and Drug Administration. (2012). FDA drug safety communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. U.S. Food and Drug Administration.
Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350(10), 1013-1022. https://doi.org/10.1056/NEJMra032426
How this MN660 Unit 8 example is structured
Her ECG finding and her lack of symptoms open the brief, because a silent effect is precisely where a mechanism explanation earns its place. Target comes before tissue: the transporter is named and set aside, then the channel is introduced with the current it carries. The electrophysiology block runs as a chain from channel to action potential to ECG to arrhythmia risk, one sentence per step. The amplifier list is arranged by mechanism, electrolytes that weaken the same current, a slower heart rate that stretches repolarization further, and additive drugs, rather than as a loose checklist. The regulatory block reports the dated communication and its basis without quoting amounts, and notes that escitalopram carries a smaller signal. The brief ends on its own limit: it explains why the risk exists and leaves any decision about her medication to her prescriber.
Get an MN660 Unit 8 example written to your instructions
Say which adverse effect your MN660 Unit 8 prompt assigns, or that any effect will do, and add its rubric. Your first brief is on us and follows those instructions exactly, arriving within 24-48h and explaining the effect from the receptor or channel responsible, through the tissue it acts in, to what a clinician would observe, with regulatory history dated. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN660 Unit 8 questions, answered
Does an ion channel count as the target the unit asks about?
Yes. Adverse effects arise from receptors, transporters, enzymes and channels alike, and the assignment is about locating the molecular cause, whatever kind of protein it is. Naming hERG and the current it carries meets the requirement more precisely than a vague reference to cardiac effects, and most instructors welcome the distinction.
Should the brief include the FDA dose limits?
Refer to the communication by date and describe its basis, but leaving the specific ceilings to the label is safer in a mechanism brief. Quoting amounts invites the paper to read as prescribing guidance, which is not what the unit assesses. Where a prompt specifically requests the regulatory limits, present them as a quotation from the source rather than as a recommendation.
Why mention escitalopram at all?
Because the comparison shows the effect is not uniform across closely related molecules, which supports a target-level explanation. A sentence noting that escitalopram carries a smaller QT signal, with its source, strengthens the argument. Expanding it into a full comparison would move the brief toward a different assignment altogether.